• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Director Leung Gabriel was granted 11,215 units of Ordinary Shares, increasing direct ownership by 14% to 92,444 units (SEC Form 4)

    6/6/25 4:21:51 PM ET
    $NVCR
    Medical/Dental Instruments
    Health Care
    Get the next $NVCR alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    LEUNG GABRIEL

    (Last) (First) (Middle)
    C/O NOVOCURE INC.
    1550 LIBERTY RIDGE DRIVE, SUITE 115

    (Street)
    WAYNE PA 19087

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    NovoCure Ltd [ NVCR ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/04/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Ordinary Shares(1) 06/04/2025 A 11,215 A $0.00 92,444 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $16.72 06/04/2025 A 16,697 06/04/2026(2) 06/04/2035 Ordinary Shares 16,697 $0.00 16,697 D
    Explanation of Responses:
    1. Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2026 annual general meeting of shareholders.
    2. Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2026 annual general meeting of shareholders.
    Remarks:
    Steven Robbins, as attorney in fact for Leung, Gabriel 06/06/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $NVCR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NVCR

    DatePrice TargetRatingAnalyst
    12/2/2024$18.00 → $30.00In-line → Outperform
    Evercore ISI
    10/16/2024$24.00 → $30.00Neutral → Buy
    H.C. Wainwright
    11/20/2023$15.00Neutral
    JP Morgan
    8/28/2023$85.00 → $25.00Buy → Neutral
    H.C. Wainwright
    8/8/2023$45.00Neutral → Overweight
    Piper Sandler
    8/4/2023$51.00Outperform
    SVB Securities
    7/31/2023$33.00Underperform → In-line
    Evercore ISI
    6/7/2023$53.00 → $46.00Underperform → Neutral
    Wedbush
    More analyst ratings

    $NVCR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Leung Gabriel was granted 11,215 units of Ordinary Shares, increasing direct ownership by 14% to 92,444 units (SEC Form 4)

      4 - NovoCure Ltd (0001645113) (Issuer)

      6/6/25 4:21:51 PM ET
      $NVCR
      Medical/Dental Instruments
      Health Care
    • Director Stafford Kristin was granted 11,215 units of Ordinary Shares, increasing direct ownership by 367% to 14,269 units (SEC Form 4)

      4 - NovoCure Ltd (0001645113) (Issuer)

      6/6/25 4:20:45 PM ET
      $NVCR
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Madden Martin J.

      4 - NovoCure Ltd (0001645113) (Issuer)

      6/6/25 4:19:11 PM ET
      $NVCR
      Medical/Dental Instruments
      Health Care

    $NVCR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • October 18, 2024 - FDA Roundup: October 18, 2024

      For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c

      10/18/24 4:16:25 PM ET
      $NVCR
      $BAX
      Medical/Dental Instruments
      Health Care

    $NVCR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

      TTFields therapy concomitant with gemcitabine and nab-paclitaxel is the first treatment to show a clinically meaningful and statistically significant improvement in overall survival (OS) for patients with unresectable, locally advanced pancreatic adenocarcinoma in a Phase 3 trial The OS benefit observed with TTFields therapy is supported by significantly improved quality of life and extended pain-free survival, a key outcome for patients with pancreatic cancer Results from PANOVA-3 accepted as a late-breaking abstract for oral presentation at ASCO and simultaneous publication in the Journal of Clinical Oncology Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) and Novocure (NASDAQ:NVCR)

      5/31/25 3:08:00 PM ET
      $NVCR
      $ZLAB
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Results From the Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

      TTFields therapy concomitant with gemcitabine and nab-paclitaxel is the first treatment to show a clinically meaningful and statistically significant improvement in overall survival (OS) for patients with unresectable, locally advanced pancreatic adenocarcinoma in a Phase 3 trial The OS benefit observed with TTFields therapy is supported by significantly improved quality of life and extended pain-free survival, a key outcome for patients with pancreatic cancer Results from PANOVA-3 accepted as a late-breaking abstract for oral presentation at ASCO and simultaneous publication in the Journal of Clinical Oncology Novocure (NASDAQ:NVCR) announced that results from the Phase 3 PANOVA-3 tr

      5/31/25 8:00:00 AM ET
      $NVCR
      Medical/Dental Instruments
      Health Care
    • Novocure Announces Upcoming Investor Events

      Novocure (NASDAQ:NVCR) announced today that management will participate in two upcoming investor events. PANOVA-3 Investor Event, May 31, 2025: Novocure will host investors on Saturday, May 31 at 8:00 p.m. ET / 7:00 p.m. CT in Chicago to review data from the successful Phase 3 PANOVA-3 clinical trial in unresectable, locally advanced pancreatic cancer. Novocure leadership will be joined by Vincent Picozzi, MD, MMM, medical oncologist and investigator in the PANOVA-3 trial, to review the results and address questions. To request in-person attendance, please contact investor relations at [email protected]. Jefferies Global Healthcare Conference, June 4, 2025: Ashley Cordova, Chi

      5/27/25 7:00:00 AM ET
      $NVCR
      Medical/Dental Instruments
      Health Care

    $NVCR
    SEC Filings

    See more
    • NovoCure Limited filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - NovoCure Ltd (0001645113) (Filer)

      6/6/25 4:26:53 PM ET
      $NVCR
      Medical/Dental Instruments
      Health Care
    • NovoCure Limited filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - NovoCure Ltd (0001645113) (Filer)

      6/2/25 6:05:55 AM ET
      $NVCR
      Medical/Dental Instruments
      Health Care
    • NovoCure Limited filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - NovoCure Ltd (0001645113) (Filer)

      4/24/25 7:02:25 AM ET
      $NVCR
      Medical/Dental Instruments
      Health Care